WVE250117C20000
- 0.05
- -0.15-75.00%
Wave Life Sciences Newsroom
Wave Life Sciences' WVE-007: A Promising New Player in Obesity Treatment
Express News | Wave Life Sciences Ltd - Expects First-in-Human Study of Wve-007 in Q1 2025
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (SiRNA Targeting INHBE) in Obesity
Express News | Wave Life Sciences Announces Submission of First Clinical Trial Application for Wve-007 (Sirna Targeting Inhbe) in Obesity
PepGen Stock Craters 35% on FDA Clinical Hold
Buy Rating for Wave Life Sciences: Favorable Regulatory Environment and Promising WVE-003 Data
Wave Life Sciences: Positioned for Growth With Promising Huntington's Treatment and Strategic Advantages
Wave Life Sciences CEO Paul Bolno Sells $750,000 in Shares
Truist Financial Maintains Wave Life Sciences(WVE.US) With Buy Rating
Wave Life Sciences to Present at Upcoming Investor Conferences
In 2025, US Biotech stocks are expected to rise significantly. jpmorgan's top pick is vertex pharmaceuticals (VRTX.US).
Vertex pharmaceuticals (Vertex) ranked first on the list of US biotechnology stock selections for 2025 released by jpmorgan.
Vertex Leads J.P. Morgan's Top Biotech Picks List for 2025
Wave Life Sciences Is Maintained at Outperform by Mizuho
Mizuho Securities Maintains Wave Life Sciences(WVE.US) With Buy Rating, Announces Target Price $22
Earnings Update: Here's Why Analysts Just Lifted Their Wave Life Sciences Ltd. (NASDAQ:WVE) Price Target To US$22.20
Wave Life Sciences Third Quarter 2024 Earnings: Misses Expectations
B.Riley Financial Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $22
HC Wainwright & Co. Reiterates Buy on WAVE Life Sciences, Maintains $22 Price Target
A Quick Look at Today's Ratings for Wave Life Sciences(WVE.US), With a Forecast Between $20 to $36
Positive FDA Feedback and Strategic Advancements Boost Wave Life Sciences' Investment Potential in Huntington's Disease